Close mobile menu×
Close mobile menu

Thomas H. Brannagan III, MD

Board Certifications: 
Neuromuscular Medicine, Clinical Neurophysiology, Neurology
Expertise in: 
Amyloidosis
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-0405

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

America's Top Doctor

Board Certifications

  • Neuromuscular Medicine
  • Clinical Neurophysiology
  • Neurology

Clinical Expertise

  • Amyloidosis
  • Peripheral Neuropathy
  • Neuropathy
  • Electromyography (EMG)

Specialties

Education & Training

  • University of Virginia School of Medicine
  • Internship: Beth Israel Medical Center
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

About Thomas Brannagan

Dr. Brannagan is the director of the Peripheral Neuropathy Center at Columbia University Medical Center. He graduated from the University of Virginia and also received his medical degree from the University of Virginia in Charlottesville. He completed his Neurology residency training at the Neurological Institute of Columbia Presbyterian Medical Center between 1991 and 1994. He subsequently did a Neuromuscular EMG fellowship at Columbia, followed by a Neuroimmunology fellowship in the laboratory of Dr. Norman Latov. Prior to returning to Columbia, Dr. Brannagan was the director of the Diabetic Neuropathy Research center at Cornell University in New York City and was co-director of the EMG laboratory at MCP-Hahnemann University in Philadelphia.

He is a member of the American Academy of Neurology, the American Neurological Association, as well as the American Association of Electrodiagnostic Medicine. He is also a member of the Neuropathy Association and the Peripheral Nerve Society. 

Academic Titles

  • Professor of Neurology at CUMC

Administrative Positions

  • Director, Peripheral Neuropathy Center
  • Director, Columbia Neuropathy Research Center
  • Co-director, Electromyography (EMG) Laboratory

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
710 West 168th Street
New York, New York 10032
Phone:
(212) 305-0405
Fax:
(212) 305-5396
Primary

Research

Dr. Brannagan's major interest is in the evaluation and treatment of peripheral neuropathy, particularly immune-mediated neuropathies and idiopathic neuropathies. His publications have focused on new treatments for chronic demyelinating polyneuropathy (CIDP), painful neuropathies, neuropathy associated with celiac disease and the use of IVIg in Neurological disorders. He has participated in numerous clinical trials of new agents to treat patients with peripheral neuropathy.

Grants

RESTORE: A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY (P&S Industry Clinical Trial)

Apr 30 2018 - Apr 30 2023

A NON-INTERVENTIONAL STUDY TO MONITOR THE SURVIVAL STATUS OF PATIENTS THAT DISCONTINUED FROM ISIS 420915-CS2 OR ISIS 420915-CS3 (P&S Industry Clinical Trial)

Feb 7 2018 - Feb 7 2023

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 6-WEEK, PARALLEL-DESIGN STUDY OF THE EFFICACY AND SAFETY OF VX-150 IN TREATING SUBJECTS WITH PAIN CAUSED BY SMALL FIBER NEUROPATHY (P&S Industry Clinical Trial)

Dec 13 2017 - Dec 13 2022

INTERNATIONAL, MULTI-CENTER, DOUBLE BLIND 9-MONTH FOLLOW-UP EXTENSION STUDY ASSESSING THE LONG TERM SAFETY AND TOLERABILITY OF PXT3003 IN PATIENTS WITH CHARCOT-MARIE-TOOTH DISEASE TYPE 1A. (P&S Industry Clinical Trial)

Aug 31 2017 - Aug 31 2022

EXPANDED ACCESS PROTOCOL OF PATISIRAN FOR PATIENTS WITH HEREDITARY TRANSTHYRETIN MEDIATED AMYLOIDOSIS (HATTR AMYLOIDOSIS) WITH POLYNEUROPATHY (P&S Industry Clinical Trial)

Apr 4 2017 - Apr 4 2022

AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF ISIS 420915 IN PATIENTS WITH FAMILIAL AMYLOID POLYNEUROPATHY (FAP) (P&S Industry Clinical Trial)

Jul 18 2014 - Jul 18 2019

PERIPHERAL NERVE DISORDERS FELLOWSHIP (Private)

Jul 1 2016 - Jun 30 2019

APOLLO: A PHASE 3 MULTICENTER, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALN-TTR02 IN TRANSTHYRETIN (TTR)-MEDIATED POLYNEUROPATHY (FAMILIAL AMYLOIDOTIC POLYNEUROPATHY-FAP) (P&S Industry Clinical Trial)

Dec 20 2013 - Dec 20 2018

A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CBX129801 (ERSATTA?), LONG-ACTING SYNTHETIC C-PEPTIDE, IN TYPE 1 DIABETES MELLITUS SUBJECTS WITH MILD TO MODERATE DIABETIC PERIPHERAL NEUROPATHY (P&S Industry Clinical Trial)

Jul 2 2013 - Jul 2 2018

A PHASE 2/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ISIS 420915 IN PATIENTS WITH FAMILIAL AMYLOID POLYNUROPATHY (P&S Industry Clinical Trial)

Apr 18 2013 - Apr 18 2018

A DOUBLE-BLIND, RANDOMIZED, MULTICENTER, PLACEBOCONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFELY OF FINGOLIMOD 0.5 MG ADMINISTERED ORALLY ONCE DAILY VERSUS PLACEBO IN PATIENTS WITH CIDP (P&S Industry Clinical Trial)

Feb 20 2013 - Feb 20 2018

PATIENT ASSISTED INTERVENTION FOR NEUROPATHY: COMPARISON OF TREATMENT IN REAL LIFE SITUATIONS (PAIN-CONTROLS) (Private)

Jul 1 2014 - Mar 31 2017

INTERNATIONAL GUILLAIN-BARRE SYNDROME OUTCOMES STUDY (IGOS) (Private)

Oct 25 2013 - Oct 24 2016

CLINICAL AND TRANSLATIONAL SCIENCE AWARD (Federal Gov)

Sep 30 2006 - Jun 30 2016

LMS-002 (P&S Industry Clinical Trial)

Jun 17 2011 - Jun 17 2016

A PLACEBO CONTROLLED, RANDOMIZED, DOUBLE BLIND TRIAL OF MILNACIPRAN FOR THE TREATMENT OF IDIOPATHIC NEUROPATHIC PAIN (P&S Industry Clinical Trial)

Dec 5 2010 - Dec 8 2015

SB-509-901 (P&S Industry Clinical Trial)

Jun 30 2010 - Jun 30 2015

PERIPHERAL NEUROPATHY FELLOWSHIP (Private)

Jul 1 2011 - Jun 30 2014